Longeveron Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage regenerative medicine biotechnology company that develops cellular therapies derived from culture-expanded mesenchymal stem cells (MSCs) sourced from bone marrow of young healthy adult donors for life-threatening and chronic aging-related conditions; its lead investigational product, laromestrocel (Lomecel-B™), targets hypoplastic left heart syndrome (HLHS) in a Phase 2b pivotal trial (ELPIS II) with top-line results expected in Q3 2026, Alzheimer's disease following completion of Phase 2a (CLEAR MIND) and positive FDA Type B meeting in March 2025 for a proposed Phase 2/3 trial, aging frailty after Phase 2 completion, and pediatric dilated cardiomyopathy with a planned Phase 2 pivotal trial in 2026; the company also generates revenue from clinical trial services and contract manufacturing. Founded in 2014 and headquartered at 1951 NW 7th Avenue, Suite 520, Life Science & Technology Park, Miami, Florida, Longeveron operates primarily in the United States with additional activities in Japan for aging frailty trials and pursues global partnerships, including with the Alzheimer's Association. Recent developments include closing an up to $17.5 million public offering in August 2025 to fund laromestrocel programs and extend runway, appointing Wa'el Hashad as Chief Executive Officer effective March 2023, and receiving Rare Pediatric Disease Designation from the FDA for HLHS with plans for a Biologics License Application submission by late 2026.
Company News
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron Announces 1-for-10 Reverse Stock Split
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Longeveron to Present at BIO International Convention 2026
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026